Aeterna Zentaris (AEZS); Die neue Dendreon ??? - 500 Beiträge pro Seite

[Massel]

Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer

http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

----------------------------------------

3 Medikamente in Phase 3 , 3 in Phase 2 und 3 in Phase 1,

mit der heutigen NEWS bald 4 in Phase 2; und das bei einer Markkapitalisierung von rund 140 MIO US.....

DAS KANN WAS WERDEN !!!

-------------------------------

gruß
massel

[Massel]

re-Market
Last: $ 2.04 Pre-Market
High: $ 2.15
Pre-Market
Volume: 1,005,482 Pre-Market
Low: $ 1.85

Read more: http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

[tradepunk]

Klingt interessant! Mal beobachten!

Danke für den Thread + Gruß, tp

Kursdaten

Börsenplatz NASDAQ
Last 2,0797 220 Stk.
Kurszeit 12.05.2010 18:04:35 Uhr
Tagesvolumen (Stück) 14 Mio.
Tageshoch / -tief 2,19 2,03
Vortageskurs (11.05.) / Kursart 1,83 VA
Veränd. Vortag +0,2497 +13,64%
Jahreshoch / -tief 1,97 (10.05) 0,79 (07.01)
52 Wochenhoch / -tief 3,25 (01.06) 0,75 (21.12)
Stammdaten

WKN 2593478
ISIN -
Symbol AEZS
Wertpapierart -
Bezeichnung AEterna Zentaris, Inc.
Indexzugehörigkeit
Handelssegment -
Währung US Dollar
Branche -
Anzahl der Aktien 74.201.000
Marktkapitalisierung 154,32 Mio.

[Massel]

Richtig fette Blocktrades als Käufe bis 2.19 US heute.....
Das verheißt Gutes für die nächsten Tage....

Die wissen schon warum sie sich eindecken....

[Massel]

Weil der Lizenznehmer KERX 2 Upgrades gestern und vorgestern bekommen hat,

Keryx Biopharma KERX Ladenburg Thalmann Buy $5 » $8
Keryx Biopharma KERX Rodman & Renshaw Mkt Outperform $6 » $8

dürfte meiner Meinung nach der Lizenzgeber Aeterna IN KÜRZE
ebenso einige UPGRADES der ANALysten erhalten.

Dies sollte den Kurs weiter nach oben treiben.
Gestern konnte man schön beobachten wie "clever" eingekauft wurde
(vielleicht von oben genannten Freundesfreunden),
fette Blocks und blos nicht zuviel Aufmerksamkeit dabei erregen,
nur dadurch wurde der Kurs unter 2,20 US gehalten....

Von mir weiterhin ein fettes "STRONG BUY"

Gruß
massel

[Massel]

Q1 Zahlen sind da !

Sehr gutes Quartal-

Aeterna schlägt Analytenerwartungen

Loss 0,09 , erwartet wurden -0,12


siehe:
http://finance.yahoo.com/news/Aeterna-Zentaris-Reports-prnew…

Gruß
massel

[Massel]

Aeterna Zentaris Q1 Loss Narrows - Quick Facts

http://www. nasdaq .com/aspx/company-news-story.aspx?storyid=201005130654rttraderusequity_0508&title=aeterna-zentaris-q1-loss-narrows---quick-facts

(RTTNews) - Aeterna Zentaris Inc. (AEZS, AEZ.TO) reported that its first-quarter net loss was US$5.9 million or US$0.09 per share, compared to a loss of US$12.4 million or US$0.23 per share, for the same period in 2009. This decrease is mainly related to lower comparative net R&D costs, lower SG&A expenses and higher foreign exchange gains, partly offset by lower comparative license fee revenues and lower sales and royalty margins, the company said.

Research and development costs, net of tax credits and grants, were US$5.7 million, compared to US$11.4 million for the same period in 2009. Selling, general and administrative expenses were US$2.8 million, compared to US$3.6 million for the same period in 2009.

Revenues were US$6.4 million, compared to US$6.1 million for the same period in 2009.

Analysts polled by Thomson Reuters expected the company to report a loss of US$0.12 per share on revenues of US$6.17 million for the quarter. Analysts' estimates typically exclude special items.

For comments and feedback: contact [e-mail]

Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

[Massel]

May 12, 2010 Market Close: $ 2.09
Pre-Market
Last: $ 2.14 Pre-Market
High: $ 2.14
Pre-Market
Volume: 5,500 Pre-Market
Low: $ 2.14

Read more: http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

[Massel]

BREAKING NEWS:


Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency


QUEBEC CITY, May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), (the "Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

Juergen Engel, Ph. D., President and CEO of Aeterna Zentaris stated, "We are very pleased with AEZS-108 gaining orphan medicinal product designation for ovarian cancer from European authorities, especially after having been recently granted orphan-drug designation by the FDA. This means that with both these orphan designations, AEZS-108 would be provided with extra market exclusivity protection in Europe as well as in the United States for the treatment of ovarian cancer. We now look forward to reporting the final results from our ongoing European Phase 2 study in ovarian and endometrial cancer, later this year."

About Orphan Medicinal Product Designation

Orphan medicinal product designation is granted by the European Commission, following a positive opinion from the COMP, to a medicinal product that is intended for the diagnosis, prevention or treatment of a life-threatening or a chronically debilitating condition affecting not more than five in 10,000 persons in the Community when the application for designation is submitted.

Orphan medicinal product designation provides the sponsor with access to the Centralized Procedure for the application for marketing authorization, protocol assistance, up to a 100% reduction in fees related to a marketing authorization application, pre-authorization inspection and post-authorization activities, and could provide ten years of market exclusivity in EU, once approved for the treatment of ovarian cancer.

About Ovarian Cancer

Ovarian cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovarian cancer accounts for 4% of all cancer diagnoses in women and 5% of all cancer deaths. Approximately 26,000 new cases and 17,000 deaths from this disease are estimated in the European community every year (Source: Gynaecologic Oncology 2004; 92:819-26). The National Cancer Institute estimates that in 2009, in the United States alone, there were 21,550 news cases of ovarian cancer and 14,600 related deaths.

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation and preferential uptake in the malignant tissue.

[Massel]

AEterna Zentaris, Inc. (AEZS) Pre-Market Trading
Pre-Market Charts | After Hours Charts
May 14, 2010 Market Close: $ 1.86
Pre-Market
Last: $ 2 Pre-Market
High: $ 2
Pre-Market
Volume: 6,100 Pre-Market
Low: $ 1.96

Read more: http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

[Massel]

http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

[Massel]

AEterna Zentaris, Inc. (AEZS) Pre-Market Trading
Pre-Market Charts | After Hours Charts
May 14, 2010 Market Close: $ 1.86
Pre-Market
Last: $ 2.06 Pre-Market
High: $ 2.10
Pre-Market
Volume: 56,183 Pre-Market
Low: $ 1.96

Read more: http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

[Massel]

http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…


Æterna Zentaris: Publication in the Journal of the National Cancer Institute Demonstrates Perifosine Single Agent Potential in Neuroblastoma Tumors


Perifosine observed to be an effective novel agent in neuroblastoma cells in vitro and in vivo

Phase 1 data of single agent perifosine as a treatment for recurrent solid tumors in pediatric patients, including neuroblastoma patients, to be presented at ASCO

QUEBEC CITY, May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced publication of an article in the May 12thJournal of the National Cancer Institute, entitled "In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine," demonstrating the single agent activity of perifosine (KRX-0401) in neuroblastoma tumor preclinical models. Neuroblastoma is the most common pediatric solid tumor. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, is currently being investigated in a Phase 1 study as a single agent treatment for recurrent solid tumors, including neuroblastoma, in pediatric patients. Perifosine is licensed to Keryx Biopharmaceuticals (Keryx) (Nasdaq: KERX), in the United States, Canada and Mexico. Aeterna Zentaris has also out-licensed perifosine to Handok in South Korea, while retaining rights for the rest of the world. Perifosine is also currently in Phase 3 trials in multiple myeloma and colorectal cancer, as well as in Phase 2 trials for multiple types of cancer.

The article states that activated Akt is a marker of decreased event-free or overall survival in neuroblastoma patients, and that the aim of this study was to investigate the effect of perifosine, an Akt inhibitor, as a single agent on neuroblastoma cell growth in vitro and in vivo. The preclinical study investigated the activity of perifosine on four human neuroblastoma cell lines, as well as on the survival, tumor growth, and activation status of Akt in mice bearing human neuroblastoma xenograft tumors. Perifosine showed a statistically significant reduction in neuroblastoma cell survival, slowed or regressed tumor growth, and increased survival in mice bearing neuroblastoma tumors. A decreased level of activated Akt was also observed in perifosine-treated neuroblastoma cells and xenograft tumors.

The investigators concluded that perifosine inhibited the activation of Akt and was an effective cytotoxic agent in neuroblastoma cells in vitro and in vivo, and that this data supports the future clinical evaluation of perifosine for the treatment of neuroblastoma tumors.

Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, "The data presented in this article are further proof of perifosine's great potential as an oral, novel, first-in- class anti-cancer treatment for multiple types of cancer, including neuroblastoma tumors for which there are currently no FDA approved drugs."

A copy of the article can be obtained at http://www.ncbi.nlm.nih.gov/pubmed/20463309.

About Perifosine

Perifosine is a novel, potentially first-in-class, oral anticancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, with evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis.

In addition to the Phase 1 study in pediatric patients, perifosine is currently in Phase 3 registration trials in multiple myeloma and advanced colorectal cancer, under Special Protocol Assessment and Fast Track designation granted by the FDA for both indications. FDA has also granted perifosine orphan-drug status for multiple myeloma. Furthermore, the European Medicines Agency (EMA) has issued a positive Scientific Advice as well as a positive opinion for Orphan Medicinal Product designation for perifosine in multiple myeloma.

Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.

About Neuroblastoma

Neuroblastoma is the most common pediatric solid tumor and is also the most frequently diagnosed neoplasm during infancy. Neuroblastoma accounts for more than 7% of malignancies in patients younger than 15 years and causes 15% of all pediatric oncology deaths. Activated Akt is believed to be highly expressed in poor prognosis neuroblastoma tumors. Infants, even those with metastatic disease, may experience complete regression of their disease with single low-dose chemotherapy or observation alone in carefully selected circumstances. However, poor prognosis patients, usually older than 18 months and who have extensive metastatic disease, may initially respond to intensive multimodality chemotherapy, but the tumors eventually recur and become resistant to chemotherapy. Approximately half of all neuroblastoma patients are diagnosed with high-risk poor prognosis disease, and these patients have an overall survival rate of less than 40%. Therefore, a major challenge is to improve the treatment efficacy in high-risk neuroblastoma patients.

There are currently no FDA approved drugs for the treatment of neuroblastoma.

Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…#ixzz0oG7hP2px

----------------------

gruß
massel

[lamona]

NEWS:
http://www.investorvillage.com/smbd.asp?mb=2934&mn=64&pt=msg…

[lunatics]

Stock to watch

Schon gut gelaufen. Derzeit überkauft. Bei einem Rückgang des Kurses Einstieg nicht verpassen!